All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance

A. Takeshita, K. Shigeno, K. Shinjo, K. Naito, K. Ohnishi, H. Hayashi, M. Tanimoto, R. Ohno

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Here the relationship between all-trans retinoic acid (ATRA)-resistance and P-glycoprotein (P-gp)-associated multidrug resistance (MDR) is discussed in acute promyelocytic leukemia (APL). First, the remission rates of ATRA therapy are similar in relapsed/refractory APL to the preceding chemotherapy given and in newly diagnosed APL. Second, MDR1 cDNA-transduced NB4 (NB4/MDR) cells accumulate less Rhodamine-123 (Rh123) than NB4 cells, but there is no difference in the intracellular ATRA concentration between them. PSC833 or MS209, MDR modifiers, increases the intracellular accumulation of Rh123 in NB4/MDR and APL cells expressing P-gp, but not of ATRA. Third, the expression of CD11b, the NBT reduction activity, the proportion of apoptotic cells and the morphology are not different between NB4/MDR and NB4 cells, and between APL cells expressing P-gp and not. APL cells express little P-gp, and mainly express CD33 but no CD34. Despite previous reports that ATRA-resistant APL cells express more P-gp than ATRA-sensitive ones, P-gp and ATRA-resistance seems to exist independently.

Original languageEnglish
Pages (from-to)739-746
Number of pages8
JournalLeukemia and Lymphoma
Volume42
Issue number4
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Multiple Drug Resistance
P-Glycoprotein
Tretinoin
Rhodamine 123
Complementary DNA
Drug Therapy

Keywords

  • Acute promyelocytic leukemia (APL)
  • All-trans retinoic acid (ATRA)
  • Multi-drug resistance (MDR)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Takeshita, A., Shigeno, K., Shinjo, K., Naito, K., Ohnishi, K., Hayashi, H., ... Ohno, R. (2001). All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance. Leukemia and Lymphoma, 42(4), 739-746.

All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance. / Takeshita, A.; Shigeno, K.; Shinjo, K.; Naito, K.; Ohnishi, K.; Hayashi, H.; Tanimoto, M.; Ohno, R.

In: Leukemia and Lymphoma, Vol. 42, No. 4, 2001, p. 739-746.

Research output: Contribution to journalArticle

Takeshita, A, Shigeno, K, Shinjo, K, Naito, K, Ohnishi, K, Hayashi, H, Tanimoto, M & Ohno, R 2001, 'All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance', Leukemia and Lymphoma, vol. 42, no. 4, pp. 739-746.
Takeshita, A. ; Shigeno, K. ; Shinjo, K. ; Naito, K. ; Ohnishi, K. ; Hayashi, H. ; Tanimoto, M. ; Ohno, R. / All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance. In: Leukemia and Lymphoma. 2001 ; Vol. 42, No. 4. pp. 739-746.
@article{88f4cbc2ea15447ba5c5167e7e156a88,
title = "All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance",
abstract = "Here the relationship between all-trans retinoic acid (ATRA)-resistance and P-glycoprotein (P-gp)-associated multidrug resistance (MDR) is discussed in acute promyelocytic leukemia (APL). First, the remission rates of ATRA therapy are similar in relapsed/refractory APL to the preceding chemotherapy given and in newly diagnosed APL. Second, MDR1 cDNA-transduced NB4 (NB4/MDR) cells accumulate less Rhodamine-123 (Rh123) than NB4 cells, but there is no difference in the intracellular ATRA concentration between them. PSC833 or MS209, MDR modifiers, increases the intracellular accumulation of Rh123 in NB4/MDR and APL cells expressing P-gp, but not of ATRA. Third, the expression of CD11b, the NBT reduction activity, the proportion of apoptotic cells and the morphology are not different between NB4/MDR and NB4 cells, and between APL cells expressing P-gp and not. APL cells express little P-gp, and mainly express CD33 but no CD34. Despite previous reports that ATRA-resistant APL cells express more P-gp than ATRA-sensitive ones, P-gp and ATRA-resistance seems to exist independently.",
keywords = "Acute promyelocytic leukemia (APL), All-trans retinoic acid (ATRA), Multi-drug resistance (MDR)",
author = "A. Takeshita and K. Shigeno and K. Shinjo and K. Naito and K. Ohnishi and H. Hayashi and M. Tanimoto and R. Ohno",
year = "2001",
language = "English",
volume = "42",
pages = "739--746",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance

AU - Takeshita, A.

AU - Shigeno, K.

AU - Shinjo, K.

AU - Naito, K.

AU - Ohnishi, K.

AU - Hayashi, H.

AU - Tanimoto, M.

AU - Ohno, R.

PY - 2001

Y1 - 2001

N2 - Here the relationship between all-trans retinoic acid (ATRA)-resistance and P-glycoprotein (P-gp)-associated multidrug resistance (MDR) is discussed in acute promyelocytic leukemia (APL). First, the remission rates of ATRA therapy are similar in relapsed/refractory APL to the preceding chemotherapy given and in newly diagnosed APL. Second, MDR1 cDNA-transduced NB4 (NB4/MDR) cells accumulate less Rhodamine-123 (Rh123) than NB4 cells, but there is no difference in the intracellular ATRA concentration between them. PSC833 or MS209, MDR modifiers, increases the intracellular accumulation of Rh123 in NB4/MDR and APL cells expressing P-gp, but not of ATRA. Third, the expression of CD11b, the NBT reduction activity, the proportion of apoptotic cells and the morphology are not different between NB4/MDR and NB4 cells, and between APL cells expressing P-gp and not. APL cells express little P-gp, and mainly express CD33 but no CD34. Despite previous reports that ATRA-resistant APL cells express more P-gp than ATRA-sensitive ones, P-gp and ATRA-resistance seems to exist independently.

AB - Here the relationship between all-trans retinoic acid (ATRA)-resistance and P-glycoprotein (P-gp)-associated multidrug resistance (MDR) is discussed in acute promyelocytic leukemia (APL). First, the remission rates of ATRA therapy are similar in relapsed/refractory APL to the preceding chemotherapy given and in newly diagnosed APL. Second, MDR1 cDNA-transduced NB4 (NB4/MDR) cells accumulate less Rhodamine-123 (Rh123) than NB4 cells, but there is no difference in the intracellular ATRA concentration between them. PSC833 or MS209, MDR modifiers, increases the intracellular accumulation of Rh123 in NB4/MDR and APL cells expressing P-gp, but not of ATRA. Third, the expression of CD11b, the NBT reduction activity, the proportion of apoptotic cells and the morphology are not different between NB4/MDR and NB4 cells, and between APL cells expressing P-gp and not. APL cells express little P-gp, and mainly express CD33 but no CD34. Despite previous reports that ATRA-resistant APL cells express more P-gp than ATRA-sensitive ones, P-gp and ATRA-resistance seems to exist independently.

KW - Acute promyelocytic leukemia (APL)

KW - All-trans retinoic acid (ATRA)

KW - Multi-drug resistance (MDR)

UR - http://www.scopus.com/inward/record.url?scp=0034872036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034872036&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 739

EP - 746

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -